Unicycive Therapeutics Inc. (UNCY)
NASDAQ (CM) NASDAQ (CM) Primary Summary
Unicycive Therapeutics: A Catalyst Play With Real Fundamental Upside
Unicycive Therapeutics is valued at $8/share, with $2/share in cash and the pipeline—primarily OLC—valued at $6/share. OLC targets hyperphosphatemia by reducing pill burden, aiming for improved patient adherence, with a PDUFA date set for June 29, 2026. Key risks include payer acceptance of premium pricing, patent term uncertainty, and lack of outcomes data supporting improved adherence.
Unicycive Therapeutics, Inc. (UNCY) Presents at 25th Annual Needham Virtual Healthcare Conference Transcript
Unicycive Therapeutics, Inc. (UNCY) Presents at 25th Annual Needham Virtual Healthcare Conference Transcript
Unicycive Therapeutics, Inc. (NASDAQ:UNCY) Receives Consensus Rating of “Moderate Buy” from Analysts
Unicycive Therapeutics, Inc. (NASDAQ: UNCY - Get Free Report) has earned an average recommendation of "Moderate Buy" from the five analysts that are covering the stock, Marketbeat.com reports. One research analyst has rated the stock with a sell rating and four have issued a buy rating on the company. The average 12-month price target among brokers
Unicycive Therapeutics Inc. Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
| ABB Alexander Bjornager Bonde Danske Bank A/S | 1 | $5 | $5.19 | $0.19 | 3.8% |
| JD Jim Dushek HARBOUR INVESTMENTS Inc. | 100 | $477 | $506.18 | $29.18 | 6.12% |
| DP Drew Phillips Fortitude Family Office LLC | 75 | $494 | $371.25 | -$122.75 | -24.85% |
| HFT Hui Fai Tam Caitong International Asset Management Co. Ltd. | 5 | $33 | $24.75 | -$8.25 | -25% |
 Zachary Canonico DIADEMA PARTNERS LP | 106,083 | $698,026 | $534,127.9 | -$163,898.1 | -23.48% |
Unicycive Therapeutics Inc. Analysts
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
 Ed Arce WestPark Capital | -45,754.6 | $202,692.9 | $229,688.11 | -$26,995.21 | -13.32% |
 Vamil Divan Guggenheim | -60,432.61 | $404,144.09 | $325,127.43 | $79,016.66 | 19.55% |
 Mayank Mamtani B. Riley Securities | -104,070.89 | $749,310.42 | $522,435.87 | $226,874.55 | 30.28% |
| RL Robert LeBoyer Noble Capital Markets | 157,680.9 | $832,555.14 | $791,558.11 | -$40,997.03 | -4.92% |
Unicycive Therapeutics Inc. (UNCY) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Unicycive Therapeutics Inc. ever had a stock split?
Unicycive Therapeutics Inc. Profile
| Biotechnology Industry | Healthcare Sector | Shalabh K. Gupta CEO | NASDAQ (CM) Exchange | 90466Y202 CUSIP |
| US Country | 21 Employees | - Last Dividend | 20 Jun 2025 Last Split | 12 Jul 2021 IPO Date |
Overview
Unicycive Therapeutics, Inc. is a biotechnology enterprise focused on the innovation of new treatments for kidney diseases within the United States. Established in 2016, the company has positioned itself in the healthcare sector by targeting chronic kidney disease (CKD) and acute kidney injury (AKI), aiming to alleviate the burden of these conditions through groundbreaking therapeutic solutions. Headquartered in Los Altos, California, Unicycive Therapeutics is on a mission to transform the landscape of kidney disease treatment through scientific discovery and clinical application.
Products and Services
- Renazorb
A cutting-edge pharmaceutical candidate, Renazorb is being developed specifically for the management of hyperphosphatemia in patients with chronic kidney disease (CKD). Hyperphosphatemia, characterized by elevated phosphate levels in the blood, is a common and serious condition in individuals with CKD. By addressing this critical aspect of kidney disease management, Renazorb aims to improve the quality of life for those affected by CKD and mitigate the progression of the disease.
- UNI 494
UNI 494 represents Unicycive Therapeutics' innovative approach to treating acute kidney injury (AKI), a sudden episode of kidney failure or kidney damage that happens within a few hours or a few days. AKI causes a buildup of waste products in the blood and makes it hard for the kidneys to maintain the proper balance of fluids in the body. UNI 494 is in development to provide a novel treatment option that could significantly improve outcomes for patients suffering from this rapid-onset kidney condition.
